Korro Bio, Inc.

1. The Company and Liquidity

Nature of Business

Korro Bio, Inc. (together with its subsidiaries, the “Company”) is a biopharmaceutical company leveraging a novel oligonucleotide promoted editing of RNA, or OPERA, platform to develop a new class of genetic medicines forrare and highly prevalent diseases. The Company was incorporated in November 2014 as a Delaware corporation and in November 2023 completed a reverse merger with its now wholly-owned subsidiary and changed its name from Frequency Therapeutics, Inc. (“Frequency”) to Korro Bio, Inc. The Company's principal offices are in Cambridge, Massachusetts.

Risks and Uncertainties

The Company is subject to risks common to companies in the biotechnology industry including, but not limited to, new technological innovations, protection of proprietary technology, dependence on key personnel, compliance with government regulations and the need to obtain additional financing. Lead candidates and development candidates currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts will require significant amounts of additional capital, adequate personnel infrastructure and extensive compliance-reporting capabilities. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will realize revenue from product sales.

Liquidity and Capital Resources

The Company’s consolidated financial statements have been prepared on the basis of the Company continuing as a going concern. The Company expects that its existing cash, cash equivalents and marketable securities as of September 30, 2026 of $124.8 million will enable the Company to fund its planned operating expenses and capital expenditure requirements for at least 12 months from the date of issuance of these consolidated financial statements. The Company has incurred recurring losses and negative cash flows from operations since inception. As of September 30, 2026, the Company had an accumulated deficit of $439.9 million. The Company expects its operating losses and negative operating cash flows to continue into the foreseeable future. The future viability of the Company is dependent on its ability to generate cash from operating activities or to raise additional capital to finance its operations. There can be no assurance that the Company will ever earn revenues or achieve profitability, or if achieved, that the revenues or profitability will be sustained on a continuing basis. In addition, the Company’s preclinical and clinical development activities, manufacturing and commercialization of the Company’s development candidates, if approved, will require significant additional financing. However, if the Company is unable to obtain additional financing, the Company would be forced to delay, reduce or eliminate its research and development programs and/or relinquish valuable rights to its technology, lead candidates and development candidates. There is no assurance that the Company will be successful in obtaining sufficient financing on acceptable terms to continue funding its operations.

2. Basis of Presentation and Summary of Significant Accounting Policies

Basis of Presentation and Consolidation

The accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”). These consolidated financial statements have been prepared on the going concern basis of accounting, which assumes continuity of operations, realization of assets and satisfaction of liabilities in the ordinary course of business.

The consolidated financial statements include the accounts of Korro Bio, Inc. and its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.

Unaudited Interim Condensed Consolidated Financial Information

The accompanying condensed consolidated financial statements as of September 30, 2026 and for the three and nine months ended September 30, 2026 and 2025 are unaudited. The financial data and other information contained in the notes hereto as of September 30, 2026 and for the three and nine months ended September 30, 2026 and 2025 are also unaudited. The condensed consolidated balance sheet data as of December 31, 2025 was derived from the Company's audited consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2025 (the "2025 Form 10-K").

The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited annual consolidated financial statements, and in the opinion of management, reflect all adjustments, which include any normal recurring adjustments necessary for the fair presentation of the Company's interim period results. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements as of and for the year ended December 31, 2025, and the notes thereto, included in the 2025 Form 10-K.

The results for the three and nine months ended September 30, 2026 are not necessarily indicative of results to be expected for the year ended December 31, 2026, or any other interim periods, or any future year or period.

Summary of Significant Accounting Policies

The significant accounting policies used in preparation of the condensed consolidated financial statements are described in the Company's audited consolidated financial statements as of the year end December 31, 2025, and the notes thereto, which are included in the 2025 Form 10-K. Other than the warrants and treasury stock policies described below, there have been no material changes to the significant accounting policies previously disclosed in the 2025 Form 10-K.

Use of Estimates

The preparation of the Company’s consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Estimates and assumptions reflected in these consolidated financial statements include, but are not limited to accrued research and development expenses and stock-based compensation expense. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it has concluded to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates as there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ materially from those estimates or assumptions.

Warrants

The Company accounts for common stock warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in Accounting Standards Codification (“ASC”) No. 480, Distinguishing Liabilities from Equity (“ASC 480”), and ASC No. 815, Derivatives and Hedging (“ASC 815”). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, whether the warrants meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own common stock and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.

For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance and remeasured each balance sheet date thereafter. Changes in the estimated fair value of the liability-classified warrants are recognized as a non-cash gain or loss in the accompanying consolidated statements of operations and comprehensive loss.

Treasury Stock

The Company records treasury stock activities under the cost method. Treasury stock is included in authorized and issued shares but excluded from outstanding shares. The re-issuance of treasury stock is accounted for on a first-in, first-out basis and any differences between the cost of treasury stock and the re-issuance proceeds are charged or credited to additional paid-in capital.

Recent Accounting Pronouncements—Yet to be Adopted

The Company considers the applicability and impact of all Accounting Standards Updates (“ASU” or “ASUs”). Accounting standards that have been issued or proposed by the Financial Accounting Standards Board (“FASB”) or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on the Company’s consolidated financial statements upon adoption.

In November 2024, the FASB issued ASU 2024-03, Income Statement-Reporting Comprehensive Income- Expense Disaggregation Disclosures, which requires disclosure of additional information about specific expense categories in the notes to the financial statements on an interim and annual basis. The standard is effective for fiscal years beginning after December 15, 2026, and for interim periods beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the disclosure requirements related to this new standard.

3. Fair Value Measurements

The Company measures the fair value of money market funds based on quoted prices in active markets for identical securities. Cash equivalents and marketable securities include U.S. treasury bills and U.S. government agency securities that are valued either based on recent trades of securities in inactive markets or based on quoted market prices of similar instruments and other significant inputs derived from or corroborated by observable market data.

The carrying amounts reflected in the consolidated balance sheets for cash, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair values, due to their short-term nature.

Assets and liabilities measured at fair value on a recurring basis as of September 30, 2026 were as follows (in thousands):

Assets and liabilities measured at fair value on a recurring basis as of December 31, 2025 were as follows (in thousands):

The fair value of the contingent value right ("CVR") liability and the asset purchase agreement relating to Frequency’s multiple sclerosis program (the "MS APA") are based on significant unobservable inputs, which represent Level 3 measurements within the fair value hierarchy. In determining the fair value of the CVR liability and the MS APA asset, the Company used the income approach, primarily discounted cash flow models. The discounted cash flow models require the use of judgment, estimates and assumptions, including the probability of technical and regulatory success, and discount rates. For the nine months ended September 30, 2026, the aggregate change in fair value of the CVR liability and MS APA asset was less than$0.1 million. For the year ended December 31, 2025, the aggregate change in fair value of the CVR liability and MS APA asset was $0.1 million.

There were no changes in valuation techniques, nor were there any transfers among the fair value hierarchy levels during the nine months ended September 30, 2026 or during the year ended December 31, 2025.

4. Marketable Securities

Marketable securities were comprised as follows as of September 30, 2026 (in thousands):

Marketable securities were comprised as follows as of December 31, 2025 (in thousands):

The amortized cost of available-for-sale securities is adjusted for amortization of premiums and accretion of discounts to maturity. There wereno realized gains or losses on available-for-sale securities for the periods presented. None of the investments were in an unrealized loss position for greater than 12 months as of September 30, 2026. The unrealized losses on the Company's available-for-sale securities were caused by the impact of central bank and market interest rates on the investments held. The Company does not intend to sell the investments, and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost bases. After analyzing the securities in an unrealized loss position, the portion of these losses that relates to changes in credit quality is insignificant. The Company didnot record an allowance for credit losses as of September 30, 2026. Furthermore, the Company does not believe that these securities expose the Company to undue market risk or counterparty credit risk.

5. Restricted Cash

As of September 30, 2026, the Company maintained current restricted cash of$0.0 million and non-current restricted cash of $2.4 million. As of December 31, 2025, the Company maintained current restricted cash of $1.0 million and non-current restricted cash of $2.4 million. The current restricted cash of $1.0 million as of December 31, 2025 is included under the caption “prepaid expenses and other current assets” in the Company's condensed consolidated balance sheet. All restricted cash amounts are comprised solely of letters of credit required pursuant to the Company's facility leases.

The following table provides a reconciliation of cash, cash equivalents and restricted cash as of September 30, 2026 and December 31, 2025 that sums to the total of the same amounts shown in the consolidated statements of cash flows (in thousands):

6. Property and Equipment, Net

Property and equipment, net, as of September 30, 2026 and December 31, 2025 was comprised as follows (in thousands):

Property and equipment are recorded at historical cost, net of accumulated depreciation. Depreciation expense for the three months ended September 30, 2026 and 2025 was $0.4 million and $1.2 million, respectively. Depreciation expense for the nine months ended September 30, 2026 and 2025 was$1.1 millionand $3.6 million, respectively.

7. Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities as of September 30, 2026 and December 31, 2025 were comprised as follows (in thousands):

8. Common Stock

As of September 30, 2026, the Company was authorized to issue 200,000,000 shares of common stock, $0.001 par value per share. Holders of common stock are entitled to one vote per share. In addition, holders of common stock are entitled to receive dividends, if and when declared by the Company’s Board of Directors. As of September 30, 2026, no dividends had been declared.

As of September 30, 2026 and December 31, 2025, the Company had reserved for future issuance the following number of shares of common stock:

March 2026 Private Placement

On March 9, 2026, the Company entered into a subscription agreement with certain new and existing accredited investors to sell and issue in a private placement ("PIPE"): (i) an aggregate of 4,501,928 shares of its common stock at a purchase price of $11.11 per share and (ii) pre-funded warrants to acquire an aggregate 3,148,836 shares of its common stock at a purchase price of $11.109 per pre-funded warrant. The closing of the PIPE occurred on March 10, 2026 raising aggregate gross cash proceeds of approximately $85.0 million, before deducting placement agent fees and offering expenses of approximately$4.7 million. The pre-funded warrants have an exercise price of $0.001 per share. No pre-funded warrants issued in connection with the PIPE have been exercised as of September 30, 2026.

August 2026 Warrant Exchange

On August 5, 2026, the Company entered into an exchange agreement ("Exchange") with entities affiliated with Venrock Healthcare Capital Partners ("Venrock"), pursuant to which (i) Venrock agreed to surrender an aggregate of 1,000,000 shares of the Company's common stock for no consideration, to the Company, and (ii) the Company agreed to issue pre-funded warrants to purchase an aggregate of 1,000,000 shares of its common stock, with an exercise price of $0.001 per share and no expiration date. The pre-funded warrants are exercisable immediately and have terms substantially identical to the pre-funded warrants issued in the PIPE. No pre-funded warrants issued in connection with the Exchange have been exercised as of September 30, 2026. The surrendered shares were not retired and were recorded as treasury stock of $12.1 million, based on the fair value of the Company's common stock on the date of the exchange, with a corresponding increase to additional paid-in capital for the pre-funded warrants issued.

The Company has assessed the pre-funded warrants issued in connection with the PIPE and Exchange for appropriate equity or liability classification pursuant to the Company’s accounting policy described in Note 2, Basis of Presentation and Summary of Significant Accounting Policies. During this assessment, the Company determined the pre-funded warrants are a freestanding instrument that does not meet the definition of a liability pursuant to ASC 480 and does not meet the definition of a derivative pursuant to ASC 815. The pre-funded warrants are indexed to the Company’s common stock and meet all other conditions for equity classification under ASC 815. Based on the results of this assessment, the Company concluded that the pre-funded warrants are a freestanding equity-linked financial instrument that meets the criteria for equity classification under ASC 815. Accordingly, the pre-funded warrants are classified as equity and accounted for as a component of additional paid-in capital at the time of issuance. The Company also determined that the pre-funded warrants should be included in the determination of basic and diluted earnings per share in accordance with ASC 260, Earnings per Share.

At-The-Market Equity Program

In December 2024, the Company filed a Shelf Registration Statement on Form S-3 (the "Shelf Registration Statement") with the Securities and Exchange Commission ("SEC"), which covered the offering, issuance and sale by the Company of up to an aggregate of $400.0 million of the Company's common stock, preferred stock, debt securities, units and/or warrants. The Shelf Registration Statement included a prospectus covering the offering, issuance and sale of up to $100.0 million of the Company's common stock from time to time through an "at-the-market" (“ATM”) offering under the Securities Act of 1933, as amended.

Also in December 2024, the Company entered into an Open Market Sale Agreement (the “Sales Agreement”) with TD Cowen Securities (USA) LLC ("TD Cowen"), acting as the Company's Agent and/or principal (the "Sales Agent") with respect to an ATM offering program under which the Company may from time to time, at its sole discretion, issue and sell shares of its common stock having an aggregate offering price of up to $100.0 million through the Sales Agent. TD Cowen is entitled to compensation for its services equal to up to 3.0% of the aggregate gross proceeds of any shares of common stock sold through TD Cowen under the Sales Agreement. Pursuant to the Sales Agreement, any shares will be sold pursuant to the Shelf Registration Statement filed with the SEC on December 2, 2024, including the ATM prospectus contained therein, as declared effective by the SEC on December 9, 2024. In January 2026, the Company issued 501,861 shares of common stock under the Sales Agreement for gross proceeds of $5.1 million, before deducting offering expenses of approximately $0.1 million.

9. Preferred Stock

As of September 30, 2026, the Company was authorized to issue up to 10,000,000 shares of preferred stock at a par value of $0.001 withno preferred stock shares issued or outstanding.

10. Stock-based Compensation

In April 2026, the Company's Board of Directors adopted the Korro Bio, Inc. 2026 Inducement Plan (the "Inducement Plan"). The Inducement Plan provides for the grant of non-qualified stock options, stock appreciation rights, restricted stock units, restricted stock awards, unrestricted stock awards, and dividend equivalent rights. Awards under the Inducement Plan may only be granted to new employees who were not previously an employee or director of the Company or are commencing employment with the Company followinga bona fide period of non-employment, in either case, as an inducement material to the individual's entering into employment with the Company and in accordance with the requirements of Nasdaq Listing Rule 5635(c)(4). A total of 100,000 shares of common stock were reserved for issuance under the Inducement Plan.

The Company also grants stock-based awards under its 2023 Stock Option and Incentive Plan (the "2023 Plan"), which was approved by the Company’s stockholders in November 2023. The Company also has outstanding stock option awards under the Korro Bio Ops, Inc. 2019 Plan (the "Legacy Korro 2019 Plan"), the Frequency 2014 Stock Incentive Plan (the "2014 Plan"), and the Frequency 2019 Incentive Award Plan (the "Frequency 2019 Plan"), but is no longer granting awards under these plans. The Company also issues shares under the 2023 Employee Stock Purchase Plan (the "2023 ESPP"), which was approved by the Company’s stockholders in November 2023. The first offering period under the 2023 ESPP commenced on July 1, 2026.

Stock-based Compensation Expense

Total stock-based compensation expense recognized in the consolidated statements of operations and comprehensive loss for the three and nine months ended September 30, 2026 and 2025 was as follows (in thousands):

Stock Option Activity

The fair value of stock options granted during the nine months ended September 30, 2026 and 2025 was calculated on the date of grant using the following weighted-average assumptions:

Using the Black-Scholes option pricing model, the weighted-average grant date fair value of stock options granted during the nine months ended September 30, 2026 and 2025 was$8.71 and $18.96 per share, respectively.

The following table summarizes changes in stock option activity during the nine months ended September 30, 2026 (in thousands, except share and per share amounts):

Compensation cost of $4.2 million and $5.6 million related to the options was recognized during the nine months ended September 30, 2026 and 2025, respectively. Compensation cost of $1.5 million and $1.8 million related to the options was recognized during the three months ended September 30, 2026 and 2025, respectively.

The aggregate intrinsic value of options is calculated as the difference between the exercise price of the stock options and the fair value of the Company’s common stock for those stock options that had exercise prices lower than the fair value of the common stock as of the end of the period. The aggregate intrinsic value of stock options exercised during the nine months ended September 30, 2026 and 2025 was $0.0 million and$0.4 million, respectively.

As of September 30, 2026, there was unrecognized stock-based compensation expense related to unvested stock options of $9.9 million, which the Company expects to recognize over a weighted-average period of approxima tely 2.4 years.

Restricted Stock Units

During the nine months ended September 30, 2026, the Company granted Restricted Stock Units ("RSUs") to employees of the Company. RSUs are valued at the market price of a share of the Company’s stock on the date of grant. Compensation expense for RSUs is recognized on a straight-line basis over the service period. Forfeitures are recorded in the period in which they occur.

The following table summarizes changes in RSU activity during the nine months ended September 30, 2026:

Compensation costof $3.3 million and $0.0 million related to the RSUs was recognized during the nine months ended September 30, 2026 and 2025, respectively. Compensation cost of $1.3 million and $0.0 million related to the RSUs was recognized during the three months ended September 30, 2026 and 2025, respectively. As of September 30, 2026, there was unrecognized stock-based compensation expense related to unvested RSUs of $3.3 million, which the Company expects to recognize over a weighted-average period of approximately 1.4 years.

Performance Stock Units

During the nine months ended September 30, 2026, the Company granted Performance Stock Units ("PSUs") to an employee of the Company.

PSUs are valued at the market price of a share of the Company’s stock on the date of grant. Compensation expense for PSUs is recognized on a straight-line basis over the requisite service periods when the achievement of the performance condition is determined to be probable, using management's best estimate. If a performance condition is not determined to be probable or is not met, no stock-based compensation expense is recognized, and any previously recognized expense is reversed. Forfeitures are recorded in the period in which they occur.

The following table summarizes changes in PSU activity during the nine months ended September 30, 2026:

Compensation cost of $0.7 millionand$0.0 million related to the PSUs was recognized during the nine months ended September 30, 2026 and 2025, respectively. No compensation cost related to the PSUs was recognized during the three months ended September 30, 2026 and 2025. As of September 30, 2026, there was unrecognized stock-based compensation expense related to unvested PSUs of $0.9 million, which will be recognized if and when achievement of the related performance conditions is deemed probable.

Employee Stock Purchase Plan

The 2023 ESPP allows employees to purchase shares of the Company's common stock. The purchase price is equal to 85% of the lower of the closing price of the Company’s common stock on the first day of the offering period or the last day of the offering period. The Company commenced the first offering pursuant to the 2023 ESPP on July 1, 2026, and such offering will end on November 19, 2026.

During the nine months ended September 30, 2026, no shares of common stock were purchased pursuant to the 2023 ESPP. Compensation cost of less than $0.1 million related to the 2023 ESPP was recognized during the three and nine months ended September 30, 2026. No compensation cost related to the 2023 ESPP was recognized during the three and nine months ended September 30, 2025.

11. Collaboration Agreements

Genevant Agreement

In March 2023, Legacy Korro entered into a collaboration and license agreement (the “Genevant Agreement”) with Genevant Sciences GmbH (“Genevant”). Key financial terms under the Genevant Agreement are as follows:

•

The Company made a $2.5 million payment to Genevant in March 2023 upon execution of the Genevant Agreement and recorded the payment within research and development expense in the consolidated statement of operations and comprehensive loss for the year ended December 31, 2023.

•

The Company will reimburse Genevant for certain out-of-pocket and full-time equivalent costs incurred as a result of research and development activities performed under the Genevant Agreement.

•

Genevant is entitled to receive payments from the Company upon the achievement of certain milestones, including potential clinical milestone payments of up to $13.5 million, potential regulatory and development milestone payments of up to $27.0 million, and potential commercial milestone payments up to an aggregate total of $57.0 million.

•

Genevant is eligible to receive royalties at percentage rates in the mid-single-digits, based on future annual net sales of licensed products within the scope of the Genevant Agreement.

As of December 31, 2025, development milestones of $2.5 million had been achieved. The Company recorded $0.1 million and $1.9 million within research and development expense in the condensed consolidated statement of operations and comprehensive loss during the nine months ended September 30, 2026 and 2025, respectively, related to the Genevant Agreement. The Company recorded$0.0 million and $0.1 million within research and development expense in the condensed consolidated statement of operations andcomprehensive loss during the three months ended September 30, 2026 and 2025, respectively, related to the Genevant Agreement.

Novo Nordisk Agreement

On September 13, 2024, the Company entered into a research collaboration and license agreement with Novo Nordisk A/S (“Novo Nordisk”), pursuant to which the Company granted Novo Nordisk an exclusive worldwide license under certain intellectual property rights to research, develop, manufacture, commercialize or otherwise exploit certain licensed compounds and licensed products for an initial target in the cardiometabolic field and for a second target (to be nominated by Novo Nordisk within a specified time period as set forth in the agreement). Under the agreement, the Company is responsible for certain research and development activities with respect to licensed compounds and licensed products directed against the initial target and the second target (if nominated by Novo Nordisk), and the Company is eligible to receive cost reimbursement from Novo Nordisk for the Company's performance of such research and development activities under the agreement with respect to such target(s). Novo Nordisk may undertake subsequent worldwide development, manufacturing, marketing and commercialization of the licensed products directed against the initial target and the second target (if applicable). For additional information relating to the terms of such agreement, see Note 12 in the audited consolidated financial statements included in the 2025 Form 10-K.

In October 2024, the Company received an upfront nonrefundable payment of $10.0 million from Novo Nordisk related to the first product candidate, or program target. The Company is entitled to an additional upfront nonrefundable payment from Novo Nordisk upon the selection of the second program target as well as related cost reimbursements.

The Company assessed this arrangement in accordance with ASCTopic 606, Revenue from Contracts with Customers, and concluded that the contract counterparty, Novo Nordisk, is a customer. The Company determined that the research services and the exclusive licenses granted under the collaboration agreement for the initial target are not distinct and, therefore, the Company accounts for the research services and exclusive licenses as a single performance obligation. Additionally, the Company concluded that Novo Nordisk’s option to select a second target does not give rise to a material right or performance obligation until the additional target is selected due to the additional services being priced at standalone selling price. The Company recognizes revenue related to the combined license and research services performance obligation over time using the input method. Under the input method, the extent of progress towards completion is measured based on the ratio of costs incurred to date to the total estimated costs at completion of the performance obligation, which the Company believes best measures its progress towards satisfying the combined performance obligation. A cost-based input method of revenue recognition requires management to make estimates of costs to complete the performance obligation. In making such estimates, judgment is required to evaluate assumptions related to cost estimates.

Effective November 11, 2025, the Company and Novo Nordisk entered into an amendment to the research collaboration and license agreement under which the Company and Novo Nordisk agreed to pause the research collaboration and license agreement for 12 months (the “hold period”), effective as of the date of the amendment. During the hold period, the parties agreed that all research and development activities and corresponding obligations under the agreement will be suspended without any liability or payment obligation for either party. The Company also agreed to promptly wind-down its research and development activities in connection with the license agreement and Novo Nordisk agreed to reimburse the Company for certain wind-down costs associated with the hold period. All wind-down activities were completed and reimbursed as of March 31, 2026.

As of September 30, 2026, the total transaction price was determined to be $40.0 million based on the $10.0 million upfront nonrefundable payment and $30.0 million of estimated research services for the first program target. During the nine months ended September 30, 2026 and 2025, the Company recognized total collaboration revenue of $0.0 million and $5.1 million, respectively. During the three months ended September 30, 2026 and 2025, the Company recognized total collaboration revenue of $0.0 million and $1.1 million, respectively. In November 2025, the Company agreed to a 12-month pause on such collaboration with Novo Nordisk, and accordingly, prior to receipt of the termination notice described below, the Company expected to recognize revenue through 2028.

On November 3, 2026, Novo Nordisk delivered written notice of its election to terminate the collaboration agreement in its entirety for convenience, as the agreement permits on 90 days’ prior written notice. The termination will take effect on February 1, 2027, at which time the licenses granted to Novo Nordisk under the agreement will terminate. Novo Nordisk will reimburse the Company for certain third-party wind-down costs and non-cancellable committed costs attributable to the termination. The upfront payment and other amounts previously received are non-refundable. The termination notice is a nonrecognized subsequent event, and no adjustments have been made to the condensed consolidated financial statements as of and for the three and nine months ended September 30, 2026.

The Company had$3.0 millionof current deferred revenue and $4.8 million of non-current deferred revenue as of September 30, 2026, based on the period the services were expected to be performed and/or related costs to be incurred, which was the Company's best estimate as of September 30, 2026, prior to receipt of the termination notice. As the Company has no remaining obligation to perform research services under the agreement, the Company expects to recognize the remaining deferred revenue under the agreement of approximately $7.8 million in the fourth quarter of 2026. See Note 17, Subsequent Events.

No milestones were achieved under the agreement and, as a result of the termination, the Company will not receive any milestone payments or royalties.

12. Commitments and Contingencies

Leases

The Company is party to an operating lease for 50,453 square feet of office and laboratory space at 60 First Street, Cambridge, Massachusetts (the “60 First Street Lease”). In May 2023, the Company obtained control over the space and the Company recognized the operating lease right-of-use asset and the operating lease liability of $26.8 million on the commencement date of the lease. The total rental payments over the 11-year lease are expected to be $62.1 million, including rent credits and other lease incentives per the terms of the lease. Specifically, the 60 First Street Lease provides the Company with a tenant improvement allowance of $13.1 million. The Company utilized full amount of the $13.1 million tenant improvement allowance as of December 31, 2024. The lease has a remaining term of approximately eight years. The Company has an option to extend the lease for an additional period offive years with the rent during the option period being the then fair market rent.

The maturity of undiscounted payments due under lease liabilities and the present value of those liabilities as of September 30, 2026 were as follows (in thousands):

During the fourth quarter of 2025, the Company recorded a non-cash, long-lived asset impairment charge of $15.0 million related to its operating right-of-use asset. For additional information relating to the charge, see Note 3 in the audited consolidated financial statements included in the 2025 Form 10-K.

As of September 30, 2026, the weighted average remaining lease term was 7.6 years and the weighted average incremental borrowing rate used to determine the operating lease liability was 11.2%.

The Company combines the lease and non-lease components of fixed costs in its lease arrangements as a single lease component. Variable costs, such as utilities and maintenance costs, are not included in the measurement of right-of-use assets and lease liabilities, but rather are expensed when the event determining the amount of variable consideration to be paid occurs.

The following table summarizes the effect of lease costs in the Company’s condensed consolidated statement of operations and comprehensive loss of its operating leases (in thousands):

Legal Contingencies

The Company accrues a liability for legal contingencies when it believes that it is both probable that a liability has been incurred and that the Company can reasonably estimate the amount of the loss. The Company reviews these accruals and adjusts them to reflect ongoing negotiations, settlements, rulings, advice of legal counsel and other relevant information. To the extent new information is obtained and the views on the probable outcomes of claims, suits, assessments, investigations or legal proceedings change, changes in the Company’s accrued liabilities would be recorded in the period in which such determination is made.

In addition, in accordance with the relevant authoritative guidance, for any matters in which the likelihood of material loss is at least reasonably possible, the Company will provide disclosure of the possible loss or range of loss. If a reasonable estimate cannot be made, however, the Company will provide disclosure to that effect. The Company expenses legal costs as they are incurred.

The Company was not subject to any material legal proceedings or claims as of September 30, 2026.

Indemnifications

The Company indemnifies each of its officers and directors for certain events or occurrences, subject to certain limits, while the officer or director is or was serving at the Company’s request in such capacity, as permitted under Delaware law and in accordance with the Company’s amended and restated certificate of incorporation and bylaws. The term of the indemnification period lasts as long as an officer or director may be subject to any proceeding arising out of acts or omissions of such officer or director in such capacity.

The maximum amount of potential future indemnification is unlimited; however, the Company currently holds director and officer liability insurance. This insurance allows the transfer of risk associated with the Company’s exposure and may enable the Company to recover a portion of any future amounts paid. The Company believes that the fair value of these potential indemnification obligations is minimal. Accordingly, the Company has not recognized any liabilities relating to these obligations for any period presented.

13. 401(k) Savings Plan

The Company has a defined-contribution savings plan (the “401(k) Plan”) under Section 401(k) of the Internal Revenue Code of 1986, as amended (the "IRC"). The 401(k) Plan covers all employees who meet defined minimum age and service requirements and allows participants to defer a portion of their annual compensation, subject to statutory limitations. Effective in 2025, the Company makes an employer non-elective safe harbor contribution of 3% of the participant’s salary, subject to employer match limitations under the IRC. As such, the Company made $0.3 millionand $0.4 million of contributions to the 401(k) Plan during the nine months ended September 30, 2026 and 2025, respectively.

14. Net Loss per Share

The 4,148,836 shares underlying the pre-funded warrants are included in the calculation of basic and diluted net loss per share as of September 30, 2026, as the exercise price of $0.001 per share is not substantive and the shares are issuable for little or no consideration. Shares held in treasury are excluded from the weighted-average number of shares outstanding. No pre-funded warrants were outstanding as of September 30, 2025. The following common stock equivalents have been excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive:

15. Segment Information

The Company operates and manages its business asone reportable segment andone operating segment, which is the business of discovering, developing and commercializing therapies derived from or incorporating its RNA-editing technology. The Company's chief operating decision maker ("CODM") is the chief executive officer.

The CODM assesses performance, monitors budget versus actual results, and decides how to allocate resources based on net loss that also is reported on the consolidated statements of operations and comprehensive loss. The CODM allocates resources based on the Company's available cash resources, forecasted cash flow, and expenditures on a consolidated basis, as well as an assessment of the probability of success of its research and development activities. Resource allocation decisions are informed by budgeted and forecasted expense information, along with actual expenses incurred to date. The accounting policies of the Company's single reportable segment are the same as those described in the summary of significant accounting policies. The level of disaggregation and amounts of significant segment expenses that are regularly provided to the CODM are the same as those presented in the consolidated statements of operations and comprehensive loss. Therefore, duplication of the Company’s consolidated statements of operations and comprehensive loss in this segment disclosure is not required.

The measure of segment assets is reported on the consolidated balance sheets as total consolidated assets. All long-lived assets are located in the United States. Long-lived assets primarily consist of property and equipment, net, operating lease right-of-use assets and long-term marketable securities.

Factors used in determining the reportable segment include the nature of the Company's operating activities, the organizational and reporting structure and the type of information reviewed by the CODM regularly to allocate resources and evaluate financial performance.

The Company does not have intra-entity sales or transfers.

16. Restructuring

In May 2025, the Company implemented a strategic plan to streamline its operations, including a reduction in the Company’s workforce by approximately 20%. In November 2025, the Company implemented a strategic restructuring to extend cash runway, including a reduction in the Company’s workforce by approximately 34%.

During the three months ended June 30, 2025, the Company recorded a one-time restructuring charge of $1.2 million related to the May 2025 workforce reduction, including employee severance, benefits and related termination costs, which are included under the caption “Restructuring charge” in the Company’s consolidated statement of operations and comprehensive loss. During the year ended December 31, 2025, all activities related to the May 2025 workforce reduction were completed. During the nine months ended September 30, 2026, all activities related to the November 2025 workforce reduction were completed. Restructuring cost accruals are included under the caption “Accrued expenses and other current liabilities” in the Company's condensed consolidated balance sheet.

The following is a summary of the activity for the November 2025 Workforce Reduction:

17. Subsequent Events

On November 3, 2026, Novo Nordisk delivered written notice of its election to terminate the collaboration agreement in its entirety for convenience, effective February 1, 2027 after a contractual 90 day notice period. The termination notice is a nonrecognized subsequent event; accordingly, no adjustments were made to the condensed consolidated financial statements as of September 30, 2026. As a result, the Company expects to recognize the remaining deferred revenue under the agreement of approximately $7.8 million in the fourth quarter of 2026. See Note 11, Collaboration Agreements.